PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer — Oct 8th, 2024

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for p...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer — Oct 7th, 2024

PROCEPT BioRobotics A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif....

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 — Oct 9th, 2024

PROCEPT BioRobotics SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fin...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release — Oct 21st, 2024

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual ...

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook — Oct 29th, 2024

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates. Continue reading View comments...